Trending Stocks: Eli Lilly and Company (LLY), Teva Pharmaceutical Industries Limited (TEVA)

Vetr cut Eli Lilly and from a "sell" rating to a "strong sell" rating and set a $70.44 price target on the a report on Monday, February 20th. Finally, Barclays PLC boosted their target price on Eli Lilly and from $80.00 to $85.00 and gave the company a "buy" rating in a research note on Wednesday, February 1st. Financial Architects Inc boosted its stake in Eli Lilly and by 4.5% in the third quarter. According to these analysts, the Low Revenue Estimate for Eli Lilly and Company is 5.1 Billion and the High Revenue Estimate is 5.33 Billion. Research Analysts at Zacks has the stock a rating of 3, which implies that the firms recommendation is Neutral on the company. Eli Lilly and Company P/E (price to earnings) ratio is 33.31 and Forward P/E ratio of 19.6.

Eli Lilly and Company closed its last trading session at $84.46 with the gain of 1.68%. The firm has a market capitalization of $89.31 billion, a P/E ratio of 32.94 and a beta of 0.30. Eli Lilly and has a 12 month low of $64.18 and a 12 month high of $86.14.

Eli Lilly and Company (LLY) have shown a high EPS growth of -8.00% in the last 5 years and has earnings decline of 14.10% yoy.

On October 25, 2016, it reported earnings at $0.88 a share compared with the consensus estimate of $0.96 per share (negative surprise of -8.33%). Freestone Capital Holdings LLC's holdings in Eli Lilly and were worth $1,750,000 as of its most recent filing with the SEC.

The mean revenue estimate for the current fiscal period ending March 2017 is $5.21B by 11 brokerage firms. During the same quarter in the previous year, the business posted $0.78 EPS. The company's quarterly revenue was up 7.2% on a year-over-year basis. The company reported the earnings of $0.95/Share in the last quarter where the estimated EPS by analysts was $0.98/share. Ronna Sue Cohen now owns 2,722 shares of the company's stock worth $218,000 after buying an additional 9 shares during the period. Tarbox Group Inc. now owns 1,539 shares of the company's stock worth $124,000 after buying an additional 11 shares in the last quarter. The stock stands almost -1.34% off versus the 52-week high and 33.32% away from the 52-week low.

Investment analysts at SunTrust Banks decreased their FY2019 earnings per share estimates for shares of Eli Lilly and in a research note issued to investors on Sunday. To measure price-variation, we found LLY's volatility during a week at 1.38% and during a month it has been found around 1.4%. BlackRock Fund Advisors boosted its stake in shares of Eli Lilly and by 2.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company's stock worth $114,000 after buying an additional 61 shares during the last quarter. Finally, Alpha Windward LLC raised its position in shares of Eli Lilly and by 0.9% in the third quarter.

In related news, Director R David Hoover purchased 500 shares of the business's stock in a transaction that occurred on Friday, December 16th.

The stock showed weekly upbeat performance of 0.52%, which was maintained for the month at 7.84%. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of other large investors have also bought and sold shares of the stock. The shares were sold at an average price of $80.27, for a total value of $18,462,100.00. Following the completion of the sale, the insider now directly owns 125,125,804 shares in the company, valued at $10,043,848,287.08. The insider now directly owns 4,129 shares worth $347,414.

"Humalog 200U/mL KwikPen provides physicians a new prescription option for their patients", Eli Lilly and Company (India) MD Edgard Olaizola said.

Eli Lilly and Company discovers, develops, manufactures, and sells products in one significant business segment -pharmaceutical products.

Related News: